• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting.

作者信息

Lazzaro Carlo

机构信息

Studio di Economia Sanitaria, Via Stefanardo da Vimercate, 19, Milan 20128, Italy.

Biology and Biotechnologies Department "Lazzaro Spallanzani," University of Pavia, Pavia 27100, Italy.

出版信息

Ther Adv Med Oncol. 2024 Sep 2;16:17588359241276812. doi: 10.1177/17588359241276812. eCollection 2024.

DOI:10.1177/17588359241276812
PMID:39229470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369860/
Abstract
摘要

相似文献

1
On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting.在法国背景下，吉西他滨联合纳米白蛋白紫杉醇与单用吉西他滨治疗转移性胰腺癌的成本效益分析、质量调整生命年及成本效益阈值
Ther Adv Med Oncol. 2024 Sep 2;16:17588359241276812. doi: 10.1177/17588359241276812. eCollection 2024.
2
French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients.法国多机构对吉西他滨联合纳米白蛋白结合型紫杉醇与单用吉西他滨作为转移性胰腺癌患者二线治疗的成本效益分析。
Ther Adv Med Oncol. 2024 Jun 12;16:17588359241259635. doi: 10.1177/17588359241259635. eCollection 2024.
3
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.一项关于白蛋白结合型紫杉醇（纳米白蛋白紫杉醇）联合吉西他滨与单用吉西他滨治疗转移性胰腺癌患者的意大利成本效益分析：APICE研究
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446. doi: 10.1080/14737167.2018.1464394. Epub 2018 Apr 20.
4
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.美国纳布紫杉醇联合吉西他滨与FOLFIRINOX及吉西他滨治疗转移性胰腺癌的经济学评价
J Med Econ. 2017 Apr;20(4):345-352. doi: 10.1080/13696998.2016.1269015. Epub 2016 Dec 21.
5
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.白蛋白结合型紫杉醇联合吉西他滨治疗未经治疗的转移性胰腺癌：NICE 单一技术评估的证据审查组观点。
Pharmacoeconomics. 2018 Oct;36(10):1153-1163. doi: 10.1007/s40273-018-0646-1.
6
Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.日本不可切除转移性胰腺癌患者使用nab-紫杉醇和吉西他滨联合治疗与吉西他滨单药治疗的成本-效果分析。
Value Health Reg Issues. 2022 Mar;28:54-60. doi: 10.1016/j.vhri.2021.04.003. Epub 2021 Nov 17.
7
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.纳米白蛋白结合型紫杉醇（nab-紫杉醇）联合吉西他滨治疗西班牙转移性胰腺癌的成本效用分析：PANCOSTABRAX研究结果
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):579-89. doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19.
8
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.FOLFIRINOX 对比吉西他滨联合白蛋白紫杉醇作为转移性胰腺导管腺癌一线化疗的比较。
JAMA Netw Open. 2022 Jun 1;5(6):e2216199. doi: 10.1001/jamanetworkopen.2022.16199.
9
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.比较FOLFIRINOX、白蛋白结合型紫杉醇联合吉西他滨、吉西他滨和S-1治疗转移性胰腺癌的成本效益。
Mol Clin Oncol. 2017 Jul;7(1):125-130. doi: 10.3892/mco.2017.1278. Epub 2017 May 30.
10
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.纳米白蛋白结合型紫杉醇联合吉西他滨治疗转移性胰腺腺癌：III期MPACT试验的澳大利亚亚组分析
Asia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22.

本文引用的文献

1
French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients.法国多机构对吉西他滨联合纳米白蛋白结合型紫杉醇与单用吉西他滨作为转移性胰腺癌患者二线治疗的成本效益分析。
Ther Adv Med Oncol. 2024 Jun 12;16:17588359241259635. doi: 10.1177/17588359241259635. eCollection 2024.
2
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values.法国 QALY 的价值：提出可接受参考值的新方法。
Value Health. 2020 Aug;23(8):985-993. doi: 10.1016/j.jval.2020.04.001. Epub 2020 May 30.
3
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.一项关于白蛋白结合型紫杉醇（纳米白蛋白紫杉醇）联合吉西他滨与单用吉西他滨治疗转移性胰腺癌患者的意大利成本效益分析：APICE研究
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446. doi: 10.1080/14737167.2018.1464394. Epub 2018 Apr 20.
4
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.美国纳布紫杉醇联合吉西他滨与FOLFIRINOX及吉西他滨治疗转移性胰腺癌的经济学评价
J Med Econ. 2017 Apr;20(4):345-352. doi: 10.1080/13696998.2016.1269015. Epub 2016 Dec 21.
5
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.纳米白蛋白结合型紫杉醇（nab-紫杉醇）联合吉西他滨治疗西班牙转移性胰腺癌的成本效用分析：PANCOSTABRAX研究结果
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):579-89. doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19.
6
Parametric modelling of cost data: some simulation evidence.成本数据的参数建模：一些模拟证据。
Health Econ. 2005 Apr;14(4):421-8. doi: 10.1002/hec.941.